Composition and method for affecting obesity and related conditions

• US 8,987,245 B2
• Filed: 08/18/2014
• Issued: 03/24/2015
• Est. Priority Date: 04/02/2008
• Status: Expired due to Fees

• Current Assignee: Jonathan R. Brestoff Parker, Thomas H. Reynolds IV
• Original Assignee: Thomas H. Reynolds IV
• Inventors: Parker, Jonathan R. Brestoff, Reynolds, Thomas H. IV
• Primary Examiner(s): CHONG, YONG SOO
• Application Number:
  US14/462,207
• Publication Number:
  US 20140357610A1
• Time in Patent Office: 218 Days
• Field of Search: 514/183
• US Class Current: 514/183
• CPC Class Codes: A23L 33/30 Dietetic or nutritional methods, e.g. for losing weight A23L33/10 takes precedence
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L

Abstract

A method of reducing caloric intake or food intake in a mammal in need thereof. The method including delivering an effective amount of a compound comprising manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP) or analogs thereof to a mammal over a period of time sufficient to induce a reduction in caloric intake or food intake of the mammal.

Claims

1. A method of reducing caloric intake or food intake in a mammal in need thereof comprising:

delivering an effective amount of a compound comprising manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP) or analogs thereof to a mammal over a period of time sufficient to induce a reduction in caloric intake or food intake of the mammal.

2. The method of claim 1 wherein the effective amount of the compound is an amount which further decreases appetite or desire to consume food.

3. The method of claim 1 wherein the effective amount of the compound is from about 2.5 mg/kg of body weight to about 88 mg/kg of body weight of the mammal.

4. The method of claim 1 wherein the effective amount of the compound is introduced to the mammal on a daily basis.

5. The method of claim 1 wherein the effective amount of the compound is introduced to the mammal through an oral, intravenous, rectal, transmucosal, intestinal, parenteral, intrathecal, intraventricular, intraperitoneal, transdermal, intranasal or intraocular administration route.

6. The method of claim 1 wherein the effective amount of the compound is introduced to the mammal in the form of a subcutaneous capsular dispersion.

7. The method of claim 1 wherein the mammal expresses leptin.